Fig. 7
VS-6063 increases the sensitivity of PC9GR cells to gefitinib in vivo. a Athymic nude mice with PC9GR tumours were treated with gefitinib (12.5 mg/kg) or gefitinib (12.5 mg/kg) plus VS-6063 (25 mg/kg) for 2 weeks followed by treatment cessation. The tumour volume was measured at the indicated time intervals and calculated. b, c At the end of treatment, the tumours were excised, photographed as indicated and weighed. d Western blotting was used to analyse expression of p-EGFR, p-FAK, p-AKT and p-ERK in tumour tissues of different treatment groups. e Schematic diagram depicting the roles of OPN in acquired EGFR-TKI resistance in NSCLC by activating the integrin αVβ3/FAK signalling pathway (*P < 0.05; **P < 0.01; ***P < 0.001)